For more information, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
Each 1-hour session will include 4 topic modules focused on current management, emerging research and novel agents and strategies under active investigation for lung cancer. Each event will employ an identical format that will include the following elements:
Target Audience
This activity is intended for medical oncologists and other healthcare providers involved in the treatment of lung cancer.
Learning Objectives
CME Credit Form
CME and ABIM MOC credit form links will be emailed to each participant within 5 business days of the activity.
Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation Statement
Research To Practice designates each live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.
STEERING COMMITTEE — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:
Joshua Bauml, MDConsulting Agreements: AstraZeneca Pharmaceuticals LP, Ayala Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Genentech, a member of the Roche Group, Guardant Health, Inivata, Janssen Biotech Inc, Merck, Novartis, Regeneron Pharmaceuticals Inc, Takeda Oncology; Contracted Research: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Carevive Systems, Carisma Therapeutics, Clovis Oncology, Janssen Biotech Inc, Merck, Novartis, Takeda Oncology.
Ramaswamy Govindan, MDConsulting Agreement: Inivata.
John V Heymach, MD, PhDAdvisory Committee and Consulting Agreements: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, BrightPath Biotherapeutics Co Ltd, Bristol-Myers Squibb Company, Catalyst Pharmaceuticals, EMD Serono Inc, Foundation Medicine, Genentech, a member of the Roche Group, GlaxoSmithKline, Guardant Health, Hengrui Therapeutics Inc, Janssen Biotech Inc, Kairos Venture Investments LLC, Leads Biolabs, Lilly, Mirati Therapeutics, Nexus Health Systems, Novartis, Pneuma Respiratory, Roche Laboratories Inc, Sanofi Genzyme, Spectrum Pharmaceuticals Inc, Takeda Oncology; Contracted Research: AstraZeneca Pharmaceuticals LP, GlaxoSmithKline, Spectrum Pharmaceuticals Inc; Licensing and Fees: Spectrum Pharmaceuticals Inc.
Leora Horn, MD, MScAdvisory Committee: Amgen Inc, EMD Serono Inc, Genentech, a member of the Roche Group, Xcovery; Consulting Agreements: AstraZeneca Pharmaceuticals LP, EMD Serono Inc, Genentech, a member of the Roche Group, Incyte Corporation, Merck, Xcovery; Contracted Research: Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Xcovery.
Corey J Langer, MDAdvisory Committee: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Exelixis Inc, Genentech, a member of the Roche Group, Merck, Novocure Inc, Regeneron Pharmaceuticals Inc, Takeda Oncology; Consulting Agreements: Abbott Laboratories, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, EMD Serono Inc, Exelixis Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Guardant Health, Hospira Inc, Jazz Pharmaceuticals Inc, Merck, Novartis, Novocure Inc, Pfizer Inc, Regeneron Pharmaceuticals Inc, Takeda Oncology; Contracted Research: Advantagene Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Inovio Pharmaceuticals Inc, Lilly, Mirati Therapeutics, Takeda Oncology, Trizell; Data and Safety Monitoring Board/Committee: Lilly, Oncocyte.
Benjamin Levy, MDAdvisory Committee and Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Janssen Biotech Inc, Lilly, Merck, Pfizer Inc, Takeda Oncology; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Merck.
Professor Tony SK Mok, MDAdvisory Committee: AbbVie Inc, ACEA Pharma, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cirina, CStone Pharmaceuticals, Daiichi Sankyo Inc, Fishawack Facilitate Ltd, G1 Therapeutics, Gritstone Oncology, Guardant Health, geneDecode Co Ltd, Hengrui Therapeutics Inc, Hutchison China MediTech Limited, Ignyta Inc, Incyte Corporation, IQVIA, Janssen Biotech Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Lunit Inc, Merck Serono, Merck Sharp & Dohme Corp, Mirati Therapeutics, Novartis, OncoGenex Pharmaceuticals Inc, OrigiMed, Pfizer Inc, Puma Biotechnology Inc, Roche Laboratories Inc, Sanofi-Aventis R&D, SFJ Pharmaceuticals, Takeda Oncology, Vertex Pharmaceuticals, Virtus Medical Group, Yuhan Corporation; Consulting Agreements: AbbVie Inc, ACEA Pharma, Alpha Biopharma, Amgen Inc, Amoy Diagnostics Co Ltd, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, CStone Pharmaceuticals, Daiichi Sankyo Inc, Fishawack Facilitate Ltd, Gritstone Oncology, Guardant Health, Hengrui Therapeutics Inc, Ignyta Inc, Incyte Corporation, IQVIA, INMED, Janssen Biotech Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Lunit Inc, Merck Serono, Merck Sharp & Dohme Corp, Mirati Therapeutics, Novartis, OncoGenex Pharmaceuticals Inc, OrigiMed, Pfizer Inc, Puma Biotechnology Inc, Roche Laboratories Inc, Sanofi-Aventis R&D, SFJ Pharmaceuticals, Takeda Oncology, Vertex Pharmaceuticals, Virtus Medical Group, Yuhan Corporation; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Clovis Oncology, G1 Therapeutics, Merck Serono, Merck Sharp & Dohme Corp, Novartis, Pfizer Inc, Roche Laboratories Inc, SFJ Pharmaceuticals, Takeda Oncology, Xcovery.
Joel W Neal, MD, PhDAdvisory Committee: Amgen Inc, AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Calithera Biosciences, Exelixis Inc, Genentech, a member of the Roche Group, Iovance Biotherapeutics, Jounce Therapeutics, Lilly, Natera Inc, Regeneron Pharmaceuticals Inc, Takeda Oncology; Contracted Research: AbbVie Inc, Adaptimmune, Boehringer Ingelheim Pharmaceuticals Inc, Exelixis Inc, Genentech, a member of the Roche Group, GlaxoSmithKline, Janssen Biotech Inc, Merck, Nektar, Novartis, Takeda Oncology.
Paul K Paik, MDAdvisory Committee: Calithera Biosciences, EMD Serono Inc, Xencor; Consulting Agreements: Bicara Therapeutics, a wholly owned subsidiary of Biocon, Boehringer Ingelheim Pharmaceuticals Inc, GlaxoSmithKline; Contracted Research: EMD Serono Inc; Data and Safety Monitoring Board/Committee: Takeda Oncology.
Nathan A Pennell, MD, PhDAdvisory Committee: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, COTA, G1 Therapeutics, Genentech, a member of the Roche Group, Inivata, Merck, Viosera Therapeutics, Xencor; Consulting Agreements: Boehringer Ingelheim Pharmaceuticals Inc, Lilly, Pfizer Inc.
Professor Solange Peters, MD, PhDAdvisory Committee and Consulting Agreements: AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biocartis, BioInvent International AB, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Clovis Oncology, Daiichi Sankyo Inc, Debiopharm Group, F Hoffmann-La Roche Ltd, Foundation Medicine, Illumina Inc, Janssen Biotech Inc, Lilly, Merck Serono, Merck Sharp & Dohme Corp, Merrimack Pharmaceuticals Inc, Novartis, Pfizer Inc, PharmaMar, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Takeda Oncology; Contracted Research: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, F Hoffmann-La Roche Ltd, Illumina Inc, Merck Serono, Merck Sharp & Dohme Corp, Novartis, Pfizer Inc; Data and Safety Monitoring Board/Committee: Academic trials.
Martin Reck, MD, PhDAdvisory Committee, Consulting Agreements and Speakers Bureau: Amgen Inc, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Lilly, Merck, Merck Sharp & Dohme Corp, Mirati Therapeutics, Novartis, Pfizer Inc, Roche Laboratories Inc; Data and Safety Monitoring Board/Committee: Sanofi Genzyme.
Lecia V Sequist, MD, MPHAdvisory Committee: AstraZeneca Pharmaceuticals LP, Janssen Biotech Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Genentech, a member of the Roche Group, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Novartis; Data and Safety Monitoring Board/Committee: Genentech, a member of the Roche Group.
David R Spigel, MDConsulting Agreements (to Institution): Amgen Inc, Aptitude Health, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Curio Biotech SA, Dracen Pharmaceuticals, EMD Serono Inc, Evelo Biosciences Inc, Exelixis Inc, Genentech, a member of the Roche Group, GlaxoSmithKline, Iksuda Therapeutics, Illumina, Intellisphere LLC, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Merck, Mirati Therapeutics, Molecular Templates, Nektar, Novartis, Novocure, Pfizer Inc, PharmaMar, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Takeda Oncology, Triptych Health Partners, TRM Oncology; Contracted Research (to Institution): Aeglea BioTherapeutics, Agios Pharmaceuticals Inc, Apollomics Inc, Astellas, AstraZeneca Pharmaceuticals LP, BIND Therapeutics Inc, Bristol-Myers Squibb Company, Calithera Biosciences, Celgene Corporation, Celldex Therapeutics, Clovis Oncology, Cyteir Therapeutics, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology, EMD Serono Inc, G1 Therapeutics, Genentech, a member of the Roche Group, GlaxoSmithKline, Grail Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, ImmunoGen Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Lilly, Merck, Molecular Partners, Nektar, Neon Therapeutics, Novartis, Novocure Inc, Takeda Oncology, Tesaro, A GSK Company, Transgene, University of Texas.
SERIES MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Turning Point Therapeutics Inc and Verastem Inc.
RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.